secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immix Biopharma, Inc. (IMMX)
CIK:        0001873835
Form:       8-K
Filed at:   2025-06-03T23:59:59+00:00
Accession:  0001641172-25-013417
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immix Biopharma enters ATM equity offering with Citizens JMP Securities
-----------------------------------------------------------------------

- Agreement allows at-the-market sales of common stock; 3% commission to Agent.
- Sales conducted under existing S-3 shelf (File No. 333-269100), filed January 2023.
- No immediate sale; company controls timing, price, and size of any offerings.
- Agent indemnified and reimbursed up to $50,000 for specified expenses.
- Shares subject to registration limits and Nasdaq rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873835/000164117225013417/0001641172-25-013417-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873835/000164117225013417/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-013417

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer